Pheochromocytoma: all 151 studies
Page 1 of 2. Open to participants first (56), then studies with results posted, then the rest; newest registration first within each.
- STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)Not yet recruitingNCT07743138Phase 2
- Zanzalintinib in Unresectable and Progressive MPGGsNot yet recruitingNCT07714551Phase 2
- An Experimental Study of Belzutifan Impact on Catecholamine MetabolismRecruitingNCT07680205Phase 2
- 211At-MABG in Adults With Advanced Neuroendocrine CancersNot yet recruitingNCT07661420Phase 1
- A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine MalignanciesNot yet recruitingNCT07621146
- Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)Not yet recruitingNCT07538791
- Prospective Cohort Study of Pheochromocytoma/ParagangliomaNot yet recruitingNCT07516275
- Multicenter Study on Cardiovascular and Metabolic Complications in Patients With Biochemically Silent Pheochromocytomas and ParagangliomasEnrolling by invitationNCT07316075
- Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and ParagangliomaRecruitingNCT07288931Not applicable
- Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting TumorsRecruitingNCT07200245
- Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/ParagangliomaRecruitingNCT07195500
- Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal TumorsEnrolling by invitationNCT07182175
- Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL TrialRecruitingNCT07167329Phase 2
- National Study of Adrenal TumoursEnrolling by invitationNCT06870396
- 18F-mFBG PET Imaging in the Evaluation of PheochromocytomaRecruitingNCT06813742
- Ivonescimab in the Treatment of Multiple Advanced TumorsRecruitingNCT06683846Phase 2
- Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingNCT06607692Phase 1/2
- Institutional Registry of Rare DiseasesRecruitingNCT06573723
- Genetic Bases of Neuroendocrine Neoplasms in Mexican PatientsRecruitingNCT06523582
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitingNCT06503146Phase 2
- [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersRecruitingNCT06479811Phase 1
- Hereditary Pheochromocytoma Assessment of Tumour ImmunologiesRecruitingNCT06444607
- The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)RecruitingNCT06440122
- Anlotinib Combined With Benmelstobart for Advanced PheochromocytomaNot yet recruitingNCT06429397Phase 2
- Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand TherapyRecruitingNCT06427798Phase 1/2
- Using the EHR to Advance Genomic Medicine Across a Diverse Health SystemRecruitingNCT06377033Not applicable
- Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World DataRecruitingNCT06229405
- Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed IndicationsNot yet recruitingNCT06121271Phase 2
- Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted AdrenalectomyRecruitingNCT06050057
- "Receptor Radionuclide Therapy With 177Lu-DOTATOCRecruitingNCT06045260Phase 2
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath TumorsRecruitingNCT06041516Phase 1
- HTL0039732 in Participants With Advanced Solid TumoursRecruitingNCT05944237Phase 1/2
- The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic TreatmentRecruitingNCT05885399Phase 2
- A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGLRecruitingNCT05885386Phase 2
- Prediction of Myocardial Injury After Laparoscopic Pheochromocytoma/ParaGangLioma ResectionRecruitingNCT05752773
- The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive PheochromocytomaRecruitingNCT05702944Phase 4
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsRecruitingNCT05636618Phase 1/2
- In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and ParagangliomaRecruitingNCT05636540Early Phase 1
- Genetic Factors and Pheochromocytomas in Neoplasia Type 2RecruitingNCT05158712
- 18F-MFBG PET/CT in the Evaluation of Neural Crest TumorRecruitingNCT05069220Early Phase 1
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)RecruitingNCT04924075Phase 2
- China Adrenal Disease RegistryRecruitingNCT04890444
- Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort StudyNot yet recruitingNCT04788927
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsRecruitingNCT04119024Phase 1
- A Prospective Cohort Study for Patients With Adrenal DiseasesEnrolling by invitationNCT03474237
- Multicenter Pheochromocytoma and Paraganglioma EvaluationRecruitingNCT03344016Not applicable
- Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ ParagangliomaRecruitingNCT03206060Phase 2
- Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated ConditionsRecruitingNCT03160274
- Familial Investigations of Childhood Cancer PredispositionRecruitingNCT03050268
- A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic PheochromocytomaAvailableNCT03015844
- Project: Every Child for Younger Patients With CancerRecruitingNCT02402244
- Expanded Access Protocol Using 131I-MIBGAvailableNCT01590680
- Adrenal Tumors - Pathogenesis and TherapyRecruitingNCT00669266
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or ParagangliomaRecruitingNCT00107289Phase 2
- Diagnosis of PheochromocytomaRecruitingNCT00004847Phase 1
- Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersRecruitingNCT00001238
- Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLsActive, not recruitingNCT04711135Phase 2Results posted
- Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyCompletedNCT04400474Phase 2Results posted
- Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
- A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/ParagangliomaTerminatedNCT04187404Phase 1/2Results posted
- Preoperative Alpha Blockade for PheochromocytomaCompletedNCT03176693Phase 3Results posted
- A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerTerminatedNCT03165721Phase 2Results posted
- Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by SurgeryCompletedNCT03008369Phase 2Results posted
- Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticActive, not recruitingNCT02721732Phase 2Results posted
- Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by SurgeryCompletedNCT02302833Phase 2Results posted
- Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaCompletedNCT01967576Phase 2Results posted
- A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related TumorsCompletedNCT01413503Phase 2Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or ParagangliomaTerminatedNCT01340794Phase 2Results posted
- A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...CompletedNCT00923481Phase 2Results posted
- A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/ParagangliomaStatus unknownNCT00874614Phase 2Results posted
- Study Of Sunitinib In Patients With Recurrent Paraganglioma/PheochromocytomaCompletedNCT00843037Phase 2Results posted
- Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/ParagangliomaCompletedNCT00458952Phase 1/2Results posted
- The IUPU-PPGL Score: A Imaging-Based Tool for Stratifying Surgical Complexity in Patients With Pheochromocytoma and Paragangliom（PPGL）CompletedNCT07412158
- Abdominal Circumference as a Predictor of Operative Time in Retroperitoneal Adrenalectomy for PheochromocytomaCompletedNCT07339241
- Correlation Between Preoperative Images of PPGL and Intraoperative HemodynamicsCompletedNCT06669481
- Side-specific Factors for Conversion in Adrenalectomy for Pheochromocytoma.CompletedNCT06330558
- 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous SystemWithdrawnNCT06233903Phase 2
- Side-specific Factors for Intraoperative Hemodynamic Instability in PheochromocytomaCompletedNCT06064370
- Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for PheochromocytomaCompletedNCT06062082
- Dexmedetomidine Infusion During Laparoscopic AdrenalectomyCompletedNCT06037135Not applicable
- Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL PatientsStatus unknownNCT06015061
- F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and ParagangliomaTerminatedNCT05948137
- A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGLStatus unknownNCT05883085Phase 2
- The Efficacy and Safety of Temozolomide in Patients With MPPGLCompletedNCT05858177Phase 2
- Study of Alpha-blockers Alone During Preoperative Preparation in Patients With PheochromocytomaCompletedNCT05803330Not applicable
- Metabolic Myopathy in EndocrinopathyTerminatedNCT05456997
- Predictors and Outcomes of Dysglycemia in Pheochromocytoma and ParagangliomaStatus unknownNCT05451134
- Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden DeathActive, not recruitingNCT05446779
- A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory TrialStatus unknownNCT05133349Phase 2
- Magnesium and Dexmedetomidine in PheochromocytomaCompletedNCT05102058
- Cardiac and Vascular Changes in Pheochromocytoma and ParagangliomaCompletedNCT05082311
- Metanephrines in Obstructive Sleep ApnoeaCompletedNCT05053685
- DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesTerminatedNCT04895748Phase 1
- Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart DiseaseStatus unknownNCT04891081
- The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or ParagangliomaCompletedNCT04860700Phase 2
- Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT)TerminatedNCT04605848Not applicable
- Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or ParagangliomaCompletedNCT04573816
- Pheochromocytoma and Hemodynamic InstabilityCompletedNCT04566406
- Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysisCompletedNCT04557072
- Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine CancerActive, not recruitingNCT04394858Phase 2